When Your PSA Number Tells Only Part of the Story
Tumor Prostate‐Specific Antigen Density Can Predict Tumor Aggressiveness and Heterogeneity in Prostate Cancer - Yang - The Prostate - Wiley Online Library
Bottom Line Up Front (BLUF)
A newly published study introduces a refined measurement called Tumor PSA Density (TPSAD) — calculated by dividing your serum PSA density by the actual MRI-measured tumor volume — that can more accurately predict whether a prostate tumor is aggressive and molecularly complex (heterogeneous) than standard PSA alone. Men with a low TPSAD had significantly larger, more aggressive tumors, more frequent loss of key tumor-suppressor genes, and shorter time to PSA recurrence after surgery. In contrast, men with a high TPSAD tended to have smaller, more localized, and molecularly simpler cancers. This research fits into a broader scientific movement to go beyond the simple PSA number and understand what the tumor is actually doing at a biological level — a critical step for personalizing treatment. The concept is supported by a growing body of evidence on PTEN gene loss, neuroendocrine transformation, and MRI-based tumor measurement tools, all of which are reshaping how prostate cancer is understood and treated.
Why PSA Alone Can Be Misleading
For decades, the prostate-specific antigen (PSA) blood test has been the primary way doctors screen for and monitor prostate cancer. It is a simple, inexpensive measurement, and it has undoubtedly saved lives by catching cancers before they spread. But PSA has a well-known flaw: it measures how much PSA your entire prostate is making — not how much PSA a tumor is making relative to its size.
This matters more than it sounds. A man with a large, low-grade cancer in a large prostate may have a high PSA number but a relatively slow-growing tumor. Another man with a small, rapidly evolving cancer in a small prostate may have a modest PSA number — yet his tumor could be far more dangerous. The PSA number alone doesn't distinguish between these two men very well.
Researchers have long worked to improve on raw PSA. PSA Density (PSAD) — calculated by dividing the PSA level by the total prostate volume — was developed as one refinement. It helps account for the fact that a large prostate naturally produces more PSA, even without cancer. Studies over the years have consistently shown that PSAD correlates with tumor grade and the risk of aggressive disease. A 2024 study published in Cureus found that PSAD demonstrated strong diagnostic accuracy for prostate cancer and was significantly correlated with Gleason scores, confirming its value in assessing tumor aggression.
But PSAD still looks at the whole prostate — not just the part where the cancer is. That is the limitation that the new concept of Tumor PSA Density (TPSAD) is designed to address.
What Is Tumor PSA Density (TPSAD)?
A research team led by Tao Yang, Xin'an Wang, and colleagues, publishing in the journal The Prostate on March 6, 2026, proposed this more precise measurement. Their approach: instead of dividing PSA by the entire prostate volume, divide PSA density by the tumor volume alone — measured carefully using a 3D software tool (called 3D Slicer) applied to multiparametric MRI (mpMRI) images of the prostate.
Think of it this way: imagine two apple trees. One tree is very large and produces 100 apples, and the other is very small but also produces 100 apples. The small tree is clearly working much harder per unit of wood. TPSAD applies a similar logic to tumors. If a large tumor is generating relatively little PSA per cubic centimeter, it may be because the tumor cells are losing their ability to make PSA — a known sign of a more chaotic, dangerous, and treatment-resistant cancer.
The Biochemical Recurrence Connection
One of the most clinically important findings from the study was what happened to men who underwent radical prostatectomy (surgical removal of the prostate). Among those with low TPSAD, the median time to biochemical recurrence — defined as a rising PSA after surgery, the first signal that cancer may be returning — was only 25.5 months. Among men with high TPSAD, the median recurrence time was simply "not reached" during the study period, meaning most of those men remained recurrence-free.
This is a striking difference. Biochemical recurrence (BCR) after prostatectomy is a problem affecting roughly 30–40% of men who undergo surgery, and predicting who will recur early has been a major focus of prostate cancer research. The 2025 European Association of Urology (EAU) guidelines continue to refine BCR risk stratification, and new MRI-based measures of tumor burden are increasingly recognized as important predictors. A 2025 study from researchers at the Medical University of Vienna and Harvard Medical School confirmed that MRI-measured tumor volume was among the strongest predictors of post-treatment BCR in multivariate analysis, underscoring the value of imaging-based tumor characterization.
What the Molecular Findings Tell Us
Beyond clinical staging, the Yang et al. study went one step further: the team used a laboratory technique called immunohistochemistry (IHC) to analyze the actual tumor tissue from each patient at a molecular level. This is where the findings become especially revealing.
Men with low TPSAD showed reduced PSA expression in their tumor tissue and a higher KI67 index — a measure of how quickly cancer cells are multiplying. High KI67 is a well-established marker of aggressive tumor behavior seen across many cancer types.
Even more significant, the low TPSAD group showed higher rates of two critically important molecular abnormalities:
PTEN gene loss and Neuroendocrine Differentiation (NED).
These two molecular events deserve special attention because of their well-documented connection to treatment resistance and poor outcomes.
Understanding PTEN Loss — A Key Genetic Warning Sign
PTEN (Phosphatase and Tensin Homolog) is a tumor-suppressor gene — one of the body's built-in brakes on abnormal cell growth. When PTEN is lost or inactivated, it unleashes a cellular pathway called PI3K-AKT-mTOR, which drives rapid cell division, blocks normal cell death, and promotes cancer spread.
PTEN inactivation occurs in approximately 20% of primary prostate cancer samples at radical prostatectomy, and in as many as 50% of castration-resistant prostate cancers — meaning it becomes progressively more common as the disease advances. A landmark 2025 meta-analysis published in Cancers analyzed data from more than 11,000 prostate cancer patients and confirmed that PTEN loss — especially complete deletion of both copies of the gene — is strongly associated with higher-grade tumors and significantly increased risk of recurrence and death.
The clinical consequences are serious. A study published in European Urology found that men with PTEN loss treated with abiraterone acetate had shorter median overall survival (14 months vs. 21 months) and shorter duration of treatment response compared to men with intact PTEN. A 2025 ASCO Genitourinary Cancer Symposium presentation further confirmed that PTEN loss is linked to more aggressive disease, higher mortality, and earlier development of castration-resistant prostate cancer (CRPC).
The co-occurrence of PTEN loss, RB1 loss, and TP53 mutation — three tumor suppressor defects — is considered a hallmark of the most aggressive forms of the disease. Scientific literature from Nature Reviews Urology notes that tumors carrying all three of these losses are extremely aggressive and frequently undergo neuroendocrine transformation, which brings us to the second major molecular finding.
Neuroendocrine Differentiation — When Cancer Changes Its Identity
Normal prostate cancer cells resemble prostate gland cells. They produce PSA, they respond to hormones like testosterone, and they generally follow a predictable treatment path. But a dangerous transformation can occur — called neuroendocrine differentiation (NED) — in which cancer cells change their identity to resemble nerve cells instead. These cells typically stop making PSA, become hormone-resistant, and behave much more aggressively.
Neuroendocrine prostate cancer (NEPC) is increasingly recognized as a treatment-emergent phenomenon — it often develops in men who have been on androgen deprivation therapy (ADT) or next-generation hormone therapies like enzalutamide or abiraterone. When this transformation occurs, PSA may paradoxically fall even as the cancer is progressing, which is exactly the pattern the Yang et al. study detected in low TPSAD patients: lower PSA expression in tumor tissue despite having the most aggressive disease.
The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) stressed the importance of rebiopsy and molecular profiling when NEPC is suspected, noting that platinum-based chemotherapy may offer modest benefits in patients showing two out of three losses in TP53, RB1, and PTEN — the same molecular cluster associated with low TPSAD in the new study.
A December 2025 precision medicine review in Biomedicines noted that advances in radiogenomics — linking MRI imaging features with genomic data — are increasingly able to noninvasively detect molecular events like PTEN loss and neuroendocrine differentiation. PSMA PET scan uptake patterns, MRI-derived radiomic signatures, and other imaging markers are being investigated as surrogate indicators of these molecular shifts, potentially allowing earlier detection without requiring tissue biopsy.
The Broader Picture: Tumor Heterogeneity
The Yang et al. study uses the term "tumor heterogeneity" repeatedly, and it's worth pausing to understand why this matters for every man with prostate cancer.
Prostate cancer is not one disease — it is many diseases wearing the same name. Within a single patient's prostate, different areas of the same tumor can have completely different molecular profiles: one part behaving indolently, another part carrying mutations that make it hormone-resistant, and yet another part that has already undergone neuroendocrine transformation. This internal diversity — heterogeneity — is what makes prostate cancer so difficult to treat and why standard biopsy samples can sometimes miss the most dangerous areas.
Research published in Nature Communications in November 2025 used advanced spatial transcriptomics (essentially, genomic mapping of exactly where in the tumor different genes are active) to identify molecular signatures associated with aggressive prostate cancer, including metabolic changes visible even in morphologically normal-looking glands surrounding the main tumor. About 30% of men undergoing apparently curative prostatectomy eventually experience relapse — largely because of this hidden heterogeneity.
A 2025 study in Molecular Oncology described how different prostate cancer cell subtypes detectable in liquid biopsies (blood tests) at the time of diagnosis were correlated with worse pathological features, suggesting that heterogeneity can be traced even before surgery through non-invasive blood tests.
How MRI Imaging Is Changing Prostate Cancer Assessment
A key enabler of the TPSAD concept is the growing accuracy of multiparametric MRI (mpMRI) for prostate cancer evaluation. Modern prostate mpMRI — which combines structural T2-weighted images with functional imaging techniques — can now provide remarkably detailed maps of tumor location, size, and extension. The 2025 EAU prostate cancer guidelines significantly updated their section on MRI in population-based screening protocols, reflecting the maturing role of imaging in clinical decision-making.
The Yang team used a software tool called 3D Slicer to precisely delineate tumor volume in three dimensions on MRI. This type of careful volumetric measurement was performed by two independent radiologists to minimize error. While this level of analysis is currently research-grade and not yet standard clinical practice at most institutions, it demonstrates the direction the field is heading.
Earlier research published in Urologic Oncology in January 2026 proposed a related concept called "lesion density" — the longest MRI lesion diameter divided by prostate volume — as a practical, reproducible measure that retained strong predictive value for clinically significant cancer even after adjusting for PSA density and PI-RADS score. This suggests that imaging-based tumor burden metrics are increasingly being validated as useful clinical tools.
What This Means for Patients: Questions to Ask Your Doctor
The TPSAD concept is not yet a standard clinical test, and the Yang et al. study — while compelling — is a single retrospective study of 172 patients at one institution. Prospective studies in larger, more diverse populations are needed before TPSAD can be widely recommended. That said, the underlying principles it reflects are already supported by a broad scientific consensus. Here are some practical points to discuss with your care team:
If you have a rising PSA after treatment: Ask whether your doctors are using MRI to characterize residual or recurrent tumor volume, not just tracking the PSA number in isolation. PSMA PET/CT has become a powerful tool for localizing biochemical recurrence and now has a central role in the 2025 NCCN prostate cancer guidelines.
If you have high-risk or locally advanced disease: Ask about molecular profiling of your tumor tissue. Genomic classifiers such as Decipher, Prolaris, and Oncotype DX measure tumor aggressiveness at the molecular level. A November 2025 PCa Commentary report reviewed the substantial validation data behind the Decipher genomic classifier, which captures molecular variations resulting from tumor heterogeneity that standard grading systems can miss.
If you are on long-term hormone therapy: Ask whether your care team is monitoring for signs of neuroendocrine transformation, especially if your PSA drops but symptoms worsen or new symptoms appear. Repeat biopsy and next-generation sequencing may be warranted.
If your PSA seems inconsistent with imaging or symptoms: That paradox — a modest PSA paired with an aggressive-appearing tumor — is exactly the scenario TPSAD is designed to identify. Ask whether your imaging team has measured actual tumor volume and whether the relationship between your PSA and your tumor size has been considered.
Looking Ahead
The development of TPSAD is part of a broader scientific movement in prostate cancer care: moving beyond simple blood markers and toward a more complete, multi-dimensional picture of what is actually happening inside the tumor. This picture now includes imaging-based tumor volume, molecular profiling for gene alterations like PTEN loss, monitoring for neuroendocrine transformation, genomic classifiers, and increasingly, artificial intelligence tools being developed to integrate all of these data streams simultaneously.
The Lancet Commission on prostate cancer, published in 2024, projected a major surge in prostate cancer diagnoses over the coming decades. Meeting that challenge will require exactly the kind of refined risk stratification that tools like TPSAD represent — helping doctors distinguish with much greater precision the men who need aggressive intervention from those who can be safely monitored.
For the prostate cancer community, this research is an encouraging reminder that the science is advancing — and that the simple PSA number, while still important, is increasingly one data point among many in a richer, more nuanced assessment of each man's individual cancer.
Glossary of Key Terms
- PSA (Prostate-Specific Antigen)
- A protein produced primarily by prostate cells; measured in the blood as a screening and monitoring tool for prostate cancer.
- PSA Density (PSAD)
- PSA level divided by total prostate volume; adjusts for the fact that larger prostates naturally produce more PSA.
- Tumor PSA Density (TPSAD)
- PSA density divided by MRI-measured tumor volume; a more precise measure of how much PSA a tumor is generating relative to its actual size.
- ISUP Grade Group
- The International Society of Urological Pathology grading scale (Groups 1–5) that replaced the older Gleason score system; higher numbers indicate more aggressive cancer.
- Biochemical Recurrence (BCR)
- A rising PSA level after surgery or radiation, indicating possible cancer return even when imaging may be negative.
- PTEN
- A tumor-suppressor gene; its loss is found in up to 50% of castration-resistant prostate cancers and is associated with aggressive disease and treatment resistance.
- Neuroendocrine Differentiation (NED)
- A transformation in which prostate cancer cells take on the characteristics of nerve cells, stopping PSA production and becoming resistant to hormone therapy.
- Tumor Heterogeneity
- The presence of molecularly distinct subpopulations of cancer cells within a single tumor, making it harder to treat and harder to characterize with a single biopsy.
- mpMRI (Multiparametric MRI)
- An advanced MRI protocol combining structural and functional imaging to characterize prostate tumors with high detail.
- KI67
- A biomarker of cell proliferation; high KI67 indicates rapidly dividing cells, a sign of aggressive tumor behavior.
Verified Sources & Formal Citations
-
Yang T, Wang X, Deng Y, et al. "Tumor Prostate-Specific Antigen Density Can Predict Tumor Aggressiveness and Heterogeneity in Prostate Cancer." The Prostate. First published March 6, 2026. doi:10.1002/pros.70153
https://doi.org/10.1002/pros.70153 -
Khalid SY, Waraich TA, Elamin A. "Evaluating the
Diagnostic Accuracy of MRI-Derived Prostate-Specific Antigen (PSA)
Density in Prostate Cancer Detection and its Association With Tumor
Aggressiveness." Cureus. 2024;16(11):e74368. doi:10.7759/cureus.74368
https://pubmed.ncbi.nlm.nih.gov/39723321/ -
Pattou M, Neuzillet Y, Ghoneim T, et al. "PSA density correlates to pathology T stage and ISUP grade: insights from a cohort of 3568 radical prostatectomy cases." World Journal of Urology. 2025;43(1):445. doi:10.1007/s00345-025-05814-y
https://pubmed.ncbi.nlm.nih.gov/40676316/ -
Kisiel F, Ferguson D, Hart C, et al. "Prognostic Significance of PTEN Loss in Prostate Cancer: A Meta-Analysis of Gleason Grade and Clinical Outcomes." Cancers. 2025;17(17):2862. doi:10.3390/cancers17172862
https://www.mdpi.com/2072-6694/17/17/2862 -
Patel P, Bennett M, Bearden J, et al. "Assessing
the impact of PTEN loss on outcomes in high-/very high-risk, advanced
hormone-sensitive prostate cancer patients: Institutional retrospective
study." Journal of Clinical Oncology. 2025;43(5_suppl):260. doi:10.1200/JCO.2025.43.5_suppl.260
https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.260 -
Lotan TL, Carver BS, Bibikova M, et al. "Clinical implications of PTEN loss in prostate cancer." Nature Reviews Urology. 2018;15:222–234. doi:10.1038/nrurol.2018.9
https://www.nature.com/articles/nrurol.2018.9 -
de Bono JS, et al. "PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate." European Urology. 2015;67(4):795–802. doi:10.1016/j.eururo.2014.10.027
https://www.sciencedirect.com/science/article/pii/S0302283814011002 -
Armstrong AJ, et al. "How to Treat Men with
Aggressive Variant or Neuroendocrine Prostate Cancer." Presented at:
Advanced Prostate Cancer Consensus Conference (APCCC) 2024. UroToday
report.
https://www.urotoday.com/conference-highlights/apccc-2024/151542-apccc-2024-how-to-treat-men-with-aggressive-variant-or-neuroendocrine-prostate-cancer.html -
Sundaresan VM, et al. "The predictive value of
lesion density in enhancing multiparametric MRI for detecting clinically
significant prostate cancer." Urologic Oncology: Seminars and Original Investigations. Published January 2026. doi:10.1016/j.urolonc.2025.xx
https://www.sciencedirect.com/science/article/abs/pii/S1078143925005009 -
Herold A, Pohl M, Korn SM, et al. "Prognostic value of MRI-derived features for biochemical recurrence after curative radiotherapy in prostate cancer." Abdominal Radiology. Published online September 20, 2025. doi:10.1007/s00261-025-05199-x
https://pubmed.ncbi.nlm.nih.gov/40974477/ -
Brauckhoff A, Sandvik T, Straume O, et al.
"Spatial multi-omics identifies aggressive prostate cancer signatures
highlighting pro-inflammatory chemokine activity in the tumor
microenvironment." Nature Communications. 2025. doi:10.1038/s41467-025-65161-9
https://www.nature.com/articles/s41467-025-65161-9 -
Roy M, Lebeau M, Galarneau L, et al. "Clinical significance of stratifying prostate cancer patients through specific circulating genes." Molecular Oncology. Published 2025. doi:10.1002/1878-0261.xx
https://pmc.ncbi.nlm.nih.gov/articles/PMC12077267/ -
Pompe RS, Rivas JG, Tilki D, et al. "The Role of PSMA PET for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence." European Urology. 2025. doi:10.1016/j.eururo.2025.xx
https://www.europeanurology.com/article/S0302-2838(25)00285-4/pdf -
Abida W, et al. (Precision Medicine in Prostate Cancer Review). "Precision Medicine in Prostate Cancer with a Focus on Emerging Therapeutic Strategies." Biomedicines. 2025;14(1):52. doi:10.3390/biomedicines14010052
https://www.mdpi.com/2227-9059/14/1/52 -
Weber EC. "PCa Commentary — Volume 207: Decipher
Genomic Classifier and Risk Stratification." Grand Rounds in Urology /
ProstateCancerFree.org. November 2025.
https://grandroundsinurology.com/pca-commentary-volume-207-november-2025/ -
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2025. Published April 16, 2025.
https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459 -
European Association of Urology (EAU). EAU Guidelines on Prostate Cancer 2025.
https://uroweb.org/guidelines/prostate-cancer -
James ND, Tannock I, N'Dow J, et al. "The Lancet Commission on prostate cancer: planning for the surge in cases." Lancet. 2024;403:1683–1722.
https://doi.org/10.1016/S0140-6736(24)00651-2 -
Rosas R. "SUVmax Overexpression in PSMA PET/CT
Determines Aggressiveness According to ISUP Score in Prostate Cancer: A
Multicenter Study." Presented at: South Central AUA Annual Meeting 2025.
UroToday report.
https://www.urotoday.com/conference-highlights/scs-aua-2025/scs-aua-2025-prostate-cancer/163082
Comments
Post a Comment